Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Perspective Therapeutics Inc. (CATX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: CATX (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $13.96
1 Year Target Price $13.96
| 10 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 376.97% | Avg. Invested days 51 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 249.52M USD | Price to earnings Ratio - | 1Y Target Price 13.96 |
Price to earnings Ratio - | 1Y Target Price 13.96 | ||
Volume (30-day avg) 14 | Beta 1.18 | 52 Weeks Range 1.60 - 16.31 | Updated Date 08/30/2025 |
52 Weeks Range 1.60 - 16.31 | Updated Date 08/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.37 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.29 | Actual -0.29 |
Profitability
Profit Margin - | Operating Margin (TTM) -8289.31% |
Management Effectiveness
Return on Assets (TTM) -15.32% | Return on Equity (TTM) -31.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 61514646 | Price to Sales(TTM) 202.04 |
Enterprise Value 61514646 | Price to Sales(TTM) 202.04 | ||
Enterprise Value to Revenue 68.73 | Enterprise Value to EBITDA -21.91 | Shares Outstanding 74263000 | Shares Floating 58977439 |
Shares Outstanding 74263000 | Shares Floating 58977439 | ||
Percent Insiders 18.82 | Percent Institutions 58.72 |
Upturn AI SWOT
Perspective Therapeutics Inc.
Company Overview
History and Background
Perspective Therapeutics, Inc. (formerly Isotope Technologies Group, Inc.) is a radiopharmaceutical company focused on developing therapies for cancers with unmet needs. They are focused on using alpha-particle radiation therapy. They develop targeted radiotherapies and imaging agents for various cancers. They leverage radioisotopes, particularly Actinium-225.
Core Business Areas
- Targeted Alpha Therapy (TAT): Develops radiopharmaceuticals designed to selectively target and kill cancer cells using alpha particles. The pipeline focuses on therapies for cancers like neuroendocrine tumors, prostate cancer, melanoma and others.
- Imaging Agents: Develops imaging agents to visualize and diagnose cancer, aiding in treatment planning and monitoring.
Leadership and Structure
The leadership team consists of seasoned executives with experience in radiopharmaceuticals, oncology, and business development. The organizational structure appears to be hierarchical, with functional departments focused on research and development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- 131I-MIP: A radiopharmaceutical targeting neuroendocrine tumors (NETs). It's currently in clinical development. Competitors include Novartis' Lutathera and diagnostic agents like gallium-68 DOTATATE. Market share data is unavailable as the product is still in development. Potential revenue is dependent on successful trials and FDA approval.
- Actinium-225 labeled radiopharmaceuticals: Perspective is developing Actinium-225 labeled radiopharmaceuticals for various cancers. Actinium-225 is an alpha emitting radioisotope. Competition includes other companies working with Actinium-225, such as Bayer and Novartis. Market share and revenue data is not yet available as their products are in clinical trials.
Market Dynamics
Industry Overview
The radiopharmaceutical market is growing, driven by advancements in targeted therapies and imaging technologies. The field is competitive with large pharmaceutical companies and specialized biotech firms. Demand is increasing for personalized medicine and more effective cancer treatments.
Positioning
Perspective Therapeutics is positioning itself as a leader in targeted alpha therapy, a relatively new area of radiopharmaceuticals. Their competitive advantage lies in their focus on Actinium-225 and their development of proprietary targeting molecules.
Total Addressable Market (TAM)
The radiopharmaceutical market is estimated to reach billions of dollars, with targeted therapies representing a significant portion. Perspective is targeting niche markets within oncology, so their share of the total market will depend on the success of their clinical trials. Expected to reach $11.16 Billion by 2032.
Upturn SWOT Analysis
Strengths
- Focus on Targeted Alpha Therapy
- Proprietary Technology Platform
- Experienced Management Team
- Strong IP Portfolio
Weaknesses
- Early-Stage Clinical Development
- Limited Financial Resources
- Dependence on Regulatory Approvals
- Competition from Established Companies
Opportunities
- Growing Radiopharmaceutical Market
- Strategic Partnerships
- Expansion into New Cancer Indications
- Increased Adoption of Personalized Medicine
Threats
- Clinical Trial Failures
- Regulatory Hurdles
- Competition from Established Players
- Product Liability Risks
Competitors and Market Share
Key Competitors
- NVS
- BAYRY
Competitive Landscape
Perspective Therapeutics competes with established pharmaceutical companies and smaller biotech firms in the radiopharmaceutical space. They have an advantage in the alpha therapy area but face challenges in terms of resources and market access.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal due to the company being in early-stage development. Data unavailable.
Future Projections: Future growth depends on clinical trial success and regulatory approvals. Analyst estimates vary, but potential revenue from approved products could be significant.
Recent Initiatives: Recent initiatives include advancing clinical trials for their lead candidates, expanding their IP portfolio, and establishing strategic partnerships.
Summary
Perspective Therapeutics is an early-stage radiopharmaceutical company focused on targeted alpha therapy. Their technology has promise, but their success is highly dependent on clinical trials and regulatory approvals. They are in a competitive space and will need to continue to innovate and secure funding. Recent initiatives suggest they are working towards growth and validation of their technology.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data may be estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Perspective Therapeutics Inc.
Exchange NYSE MKT | Headquaters Seattle, WA, United States | ||
IPO Launch date 2005-11-10 | CEO & Director Mr. Johan M. Spoor | ||
Sector Healthcare | Industry Medical Devices | Full time employees 138 | |
Full time employees 138 | |||
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha; and PSV4XX, a differentiated prostate-specific membrane antigen-targeted alpha therapy. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.